← back to search

Annette C. Reboli

Twitter (United States) · US
Area of research
Infectious Diseases · Epidemiology
Research interest
Research focused on Guideline and Fluconazole, with related work in Clinical Practice, Intensive care medicine, Corpus albicans. Notable publications include 'Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America', 'Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America', and 'Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials'.
h-index
citations
6,996
works
9
NIH funding
primary concept
email

Recent publications

MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis
Journal of Antimicrobial Chemotherapy 2019cited by 86position: middledoi
Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel
Clinical Infectious Diseases 2017cited by 168position: middledoi
Roadmap for creating an accelerated three-year medical education program
Medical Education Online 2017cited by 34position: middledoi
Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Clinical Infectious Diseases 2016cited by 1,281position: middledoi
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
Clinical Infectious Diseases 2015cited by 3,983position: middledoi
Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008
PLoS ONE 2014cited by 400position: middledoi
MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting
Clinical Infectious Diseases 2014cited by 157position: middledoi
Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial
BMC Infectious Diseases 2014cited by 93position: middledoi
Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials
Clinical Infectious Diseases 2012cited by 794position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

José A. Vázquez · Augusta University5 papers (2014–2017)Peter G. Pappas · University of Alabama at Birmingham5 papers (2014–2017)David R. Andes · University of Wisconsin–Madison4 papers (2012–2016)Luis Ostrosky‐Zeichner · Texas Medical Center4 papers (2014–2017)Carol A. Kauffman · University of Arizona3 papers (2014–2016)Cornelius J. Clancy · University of Pittsburgh3 papers (2015–2017)Mindy G. Schuster · University of Pennsylvania3 papers (2014–2016) · 3 papers (2014–2016)Theoklis E. Zaoutis · National and Kapodistrian University of Athens2 papers (2015–2016)M. Hong Nguyen · University of Pittsburgh2 papers (2014–2017) · 2 papers (2014–2017)Marc A. Judson · Bridgeport Hospital2 papers (2014–2017)Kieren A. Marr · Johns Hopkins University2 papers (2015–2016)Daniel H. Kett · University of Miami1 papers (2014–2014)Kristen Rundell · The Ohio State University1 papers (2017–2017) · 1 papers (2014–2014)Bart Jan Kullberg · Radboud University Nijmegen1 papers (2012–2012)Billy Franks · Cavendish Hospital1 papers (2014–2014) · 1 papers (2017–2017)Joan Cangiarella · New York University1 papers (2017–2017)